Pharmacological properties of αβ, αβγ, αβδ, and αβπ GABARs
| Agonist/Antagonist | αβ | αβγ | αβδ | αβπ |
|---|---|---|---|---|
| GABA (μM) | 1–162-a | 6–30b c | 0.2–8d e | >12-150 |
| Diazepam (nM) | No effectf | 10–100f g | No effecte | No effect2-150 |
| Pentobarbital (μM) | 262-150 | 20–35h | +e | 262-150 |
| Loreclezole (μM) | ∼12-150 | 1c i | ∼12-150 | |
| Lanthanum (α1) (μM) | (+) 207j | |||
| Lanthanum (α5) (μM) | (−) 2972-150 | (−) 5222-150 | (−) 5402-150 | |
| Lanthanum (α6) (μM) | (−) 85j | (−) 21.8e | ||
| Alphaxalone (nM) | 3402-150 | 2202-150 | 2902-150 | |
| Pregnenolone (μM) | 132-150 | 0.72-150 | 22-150 | |
| Zinc (μM) | <5k l | >100k l | 1–5e | 22-150 |
Apparent EC/IC50 values for different compounds ability to affect recombinant GABARs. + indicates pentobarbital was able to enhance GABA-evoke currents but a full concentration response curve was not reported. No entry indicates data that has not been reported.
↵2-a Davies et al., 1997; b Burgard et al., 1996;c Donnelly and Macdonald, 1996; d Fisher and Macdonald, 1997; e Saxena and Macdonald, 1994;f Pritchett et al., 1989; g Wieland et al., 1992;h Thompson et al., 1996; i Wafford et al., 1994;j Saxena et al., 1997; k Draguhen et al., 1990;l Whiting et al., 1997.
↵2-150 Present study.